##### Product Information

##### Viread® (tenofovir disoproxil fumarate) 300 mg Tablets

**NAME OF THE MEDICINE**

VIREAD 300 mg tablets

The active substance in VIREAD is tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate is a salt of a prodrug of tenofovir. Tenofovir disoproxil fumarate is designated chemically as 9-[(*R*)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]-phosphinyl]­methoxy]propyl]adenine fumarate (1:1).

Chemical structure:



Molecular formula: C23H34O14N5P

Molecular mass: 635.52

CAS number: 202138-50-9

**DESCRIPTION**

Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25°C. The partition coefficient (log P) for tenofovir disoproxil is 1.25 and the pKa is 3.75. The active pharmaceutical product is a single enantiomer that does not undergo racemisation either *in vitro* or *in vivo*.

VIREAD tablets contain the following ingredients as excipients: *Core:* microcrystalline cellulose (E460), pregelatinised maize starch, croscarmellose sodium, lactose and magnesium stearate (E572). *Coating:* Opadry II Y-30-10671-A-(ARTG3968).

Each VIREAD tablet is light blue and almond-shaped. Each tablet is debossed on one side with the markings “GILEAD” and “4331” and on the other side with the marking “300”. The tablets are supplied in bottles with screw cap closures.

### PHARMACOLOGY

**Pharmacokinetics**

Tenofovir disoproxil fumarate is a water soluble ester prodrug of the active ingredient tenofovir. Tenofovir is converted intracellularly to tenofovir monophosphate and tenofovir diphosphate. The pharmacokinetics of tenofovir disoproxil fumarate have been evaluated in healthy volunteers and HIV-1 infected individuals. Tenofovir pharmacokinetics are similar between these populations.

***Absorption:***Following oral administration of VIREAD, tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir. The oral bioavailability of tenofovir from VIREAD in fasted patients was approximately 25%. Following oral administration of a single dose of VIREAD 300 mg to HIV-1 infected patients in the fasted state, maximum serum concentrations (Cmax) are achieved in 1.0 ± 0.4 hrs. Cmax and AUC values are 296 ± 90 ng/mL and 2287 ± 685 ng•h/mL, respectively.

***Effects of Food on Oral Absorption:*** Administration of VIREAD following a high-fat meal (~700 to 1000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC0-**∞** of approximately 40% and an increase in Cmax of approximately 14%. Food delays the time to tenofovir Cmax by approximately 1 hour. Cmax and AUC of tenofovir are 326 ± 119 ng/mL and 3324 ± 1370 ng•h/mL following multiple doses of VIREAD 300 mg once daily in the fed state, when meal content was not controlled.

***Distribution:*** After oral administration of VIREAD, tenofovir is distributed to most tissues with the highest concentrations occurring in the kidney, liver and the intestinal contents (preclinical studies). *In vitro* protein binding of tenofovir to human plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 μg/mL. The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.

***Metabolism:*** *In vitro* studies have determined that neither VIREAD nor tenofovir are substrates for the CYP450 enzymes. Moreover, at concentrations substantially higher (~ 300-fold) than those observed *in vivo*, tenofovir did not inhibit *in vitro* drug metabolism mediated by any of the major human CYP450 isoforms involved in drug biotransformation (CYP3A4, CYP2D6, CYP2C9, CYP2E1, or CYP1A1/2). Tenofovir disoproxil fumarate at a concentration of 100 μM had no effect on any of the CYP450 isoforms, except CYP1A1/2, where a small (6%) but statistically significant reduction in metabolism of CYP1A1/2 substrate was observed. Based on these data, it is unlikely that clinically significant drug-drug interactions involving VIREAD and medicinal products metabolized by CYP450 would occur.

***Excretion:*** Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.

***Linearity/non-linearity:*** The pharmacokinetics of tenofovir were independent of VIREAD dose over the dose range 75 to 600 mg and were not affected by repeated dosing at any dose level.

***Special Populations:***

***Gender:*** Pharmacokinetics of tenofovir in patients are similar with regard to gender.

***Paediatric Patients 12 Years of Age and Older:*** Steady-state pharmacokinetics of tenofovir were evaluated in eight HIV-1 infected paediatric patients (12 to <18 years). Mean (± SD) Cmax and AUCtau are 0.38 ± 0.13 μg/mL and 3.39 ± 1.22 μg•hr/mL, respectively. Tenofovir exposure achieved in paediatric patients aged 12 years of age and older receiving oral daily doses of VIREAD 300 mg were similar to exposures achieved in adults receiving once-daily doses of VIREAD 300 mg.

Tenofovir exposure in HBV infected paediatric patients (12 to <18 years of age) receiving oral daily dose of VIREAD 300 mg tablet was similar to exposures achieved in adults receiving once-daily doses of VIREAD 300 mg.

Pharmacokinetic studies have not been performed with in paediatric subjects < 12 years of age.

***Elderly Patients:*** Pharmacokinetic studies have not been performed in the elderly (> 65 years).

***Ethnicity:*** Pharmacokinetics have not been specifically studied in different ethnic groups.

***Renal impairment:*** The pharmacokinetics of tenofovir are altered in subjects with renal impairment (See PRECAUTIONS). In non-HIV and non-HBV infected subjects with creatinine clearance <50 mL/min or with end‑stage renal disease (ESRD) requiring dialysis, Cmax, and AUC0‑∞ of tenofovir were increased (Table 1). It is required that the dosing interval for VIREAD be modified in patients with creatinine clearance <50 mL/min or in patients with ESRD who require dialysis (see DOSAGE AND ADMINISTRATION).

**Table 1. Pharmacokinetic Parameters (Mean±SD) of Tenofovir\* in Patients with varying Degrees of Renal Function**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Baseline Creatinine Clearance (mL/min)** 1 | **>80  (N=3)** | **50-80 (N=10)** | **30-49  (N=8)** | **12-29 (N=11)** |
| Cmax (ng/mL) | 335.5 ± 31.8 | 330.4 ± 61.0 | 372.1 ± 156.1 | 601.6 ± 185.3 |
| AUC 0-∞ (ng•hr/mL) | 2184.5 ± 257.4 | 3063.8 ± 927.0 | 6008.5 ± 2504.7 | 15984.7 ± 7223.0 |
| CL/F(mL/min) | 1043.7 ± 15.4 | 807.7 ± 279.2 | 444.4 ± 209.8 | 177.0 ± 97.1 |
| CLrenal (mL/min) | 243.5 ± 33.3 | 168.6 ± 27.5 | 100.6 ± 27.5 | 43.0 ± 31.2 |

\*300 mg, single dose of VIREAD

1 Creatinine clearance calculated using the Cockcroft Gault equation

Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour haemodialysis session removed approximately 10% of the administered tenofovir dose.

***Hepatic impairment:*** The pharmacokinetics of tenofovir following a 300 mg single dose of VIREAD have been studied in non-HIV and non-HBV infected subjects with moderate to severe hepatic impairment. There were no substantial alterations in tenofovir pharmacokinetics in patients with hepatic impairment compared with unimpaired patients. No change in VIREAD dosing is required in patients with hepatic impairment.

***Pharmacokinetic/pharmacodynamic relationship:*** VIREAD has demonstrated a dose related significant and sustained anti-HIV effect at doses ranging from 75 mg to 300 mg.

***Drug interactions:***  At concentrations substantially higher (~ 300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the following human CYP450 isoforms: CYP3A4, CYP2D6, CYP2C9 or CYP2E1. However, a small (6%) but statistically significant reduction in metabolism of CYP1A substrate was observed. Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low (see Pharmacokinetics).

Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. Co-administration of VIREAD with drugs that are eliminated by active tubular secretion may increase serum concentrations of either tenofovir or the co-administered drug, due to competition for this elimination pathway. Drugs that decrease renal function may also increase serum concentrations of tenofovir.

VIREAD has been evaluated in healthy volunteers in combination with abacavir, didanosine, efavirenz, emtricitabine (Emtriva®), entecavir, indinavir, lamivudine (3TC), lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirin saquinavir/ritonavir and tacrolimus. Tables 2 and 3 summarise pharmacokinetic effects of co-administered drug on tenofovir pharmacokinetics and effects of VIREAD on the pharmacokinetics of co-administered drug.

When unboosted atazanavir (400 mg) was co-administered with tenofovir disoproxil fumarate, atazanavir increased tenofovir Cmax by 14% and AUC by 24%. Similarly, lopinavir (400 mg)/ritonavir (100 mg) increased tenofovir AUC by 32%.

Co-administration of tenofovir disoproxil fumarate with didanosine and atazanavir results in changes in the pharmacokinetics of didanosine and atazanavir that may be of clinical significance. Table 4 summarises the drug interaction between VIREAD and didanosine. When administered with multiple doses of VIREAD, the Cmax and AUC of didanosine 400 mg increased significantly. The mechanism of this interaction is unknown. When didanosine 250 mg enteric-coated capsules were administered with VIREAD, systemic exposures to didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions (see PRECAUTIONS).

Table 2. Drug Interactions: Changes in Pharmacokinetic Parameters for Tenofovir1 in the Presence of the Co-administered Drug

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Co-administered Drug** | **Dose of Co-administered Drug (mg)** | **N** | **% Change of Tenofovir Pharmacokinetic Parameters2**  **(90% CI)** | | |
| **Cmax** | **AUC** | **Cmin** |
| Abacavir | 300 once | 8 | ⬄ | ⬄ | NC |
| Atazanavir3 | 400 once daily x 14 days | 33 | ↑ 14  (↑ 8 to ↑ 20) | ↑ 24  (↑ 21 to ↑ 28) | ↑ 22  (↑ 15 to ↑ 30) |
| Didanosine (enteric-coated) | 400 once | 25 | ⬄ | ⬄ | ⬄ |
| Didanosine (buffered)4 | 250 or 400 once daily x 7 days | 14 | ⬄ | ⬄ | ⬄ |
| Efavirenz | 600 once daily x 14 days | 29 | ⬄ | ⬄ | ⬄ |
| Emtricitabine (Emtriva) | 200 once daily x 7 days | 17 | ⬄ | ⬄ | ⬄ |
| Entecavir | 1 mg once daily x 10 days | 28 | ⬄ | ⬄ | ⬄ |
| Indinavir | 800 three times daily x 7 days | 13 | ↑ 14  (↓ 3 to ↑ 33) | ⬄ | ⬄ |
| Lamivudine | 150 twice daily x 7 days | 15 | ⬄ | ⬄ | ⬄ |
| Lopinavir/ Ritonavir | 400/100 twice daily x 14 days | 24 | ⬄ | ↑ 32  (↑ 26 to ↑ 38) | ↑ 51  (↑ 32 to ↑ 66) |
| Methadone5 | 40-110 once daily x 14 days6 | 13 | ⬄ | ⬄ | ⬄ |
| Nelfinavir | 1250 twice daily x 14 days | 29 | ⬄ | ⬄ | ⬄ |
| Oral Contraceptives7 | Ethinyl Estradiol/  Norgestimate (Ortho-Tricyclen®)  Once daily x 7 days | 20 | ⬄ | ⬄ | ⬄ |
| Ribavirin | 600 once | 22 | ⬄ | ⬄ | NC |
| Saquinavir/ Ritonavir | 1000/100 twice daily x 14 days | 35 | ⬄ | ⬄ | ↑ 23  (↑ 16 to ↑ 30) |
| Tacrolimus8 | 0.05 mg/kg twice daily x 7 days | 21 | ↑ 13  (↑1 to ↑ 27) | ⬄ | ⬄ |

1. Subjects received VIREAD 300 mg once daily.
2. Increase = ↑; Decrease = ↓; No Effect = ⬄; NC = Not Calculated
3. REYATAZTM Prescribing Information (Bristol-Myers Squibb)
4. Includes 4 subjects weighing <60 kg receiving ddI 250 mg
5. R-(active), S-and total methadone exposures were equivalent when dosed alone or with VIREAD.
6. Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.
7. Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with VIREAD.
8. Subjects received tenofovir DF 300 mg once daily as the combination product TRUVADA.

Following multiple dosing to HIV- and HBV-negative subjects receiving either chronic methadone maintenance therapy or oral contraceptives, steady state tenofovir pharmacokinetics were similar to those observed in previous studies, indicating lack of clinically significant drug interactions between these agents and VIREAD. In a study conducted in healthy volunteers dosed with a single 600 mg dose of ribavirin, no clinically significant drug interactions were observed between tenofovir disoproxil fumarate and ribavirin.

Table 3. Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of VIREAD

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Co-administered Drug** | **Dose of Co-administered Drug (mg)** | **N** | **% Change of Co-administered Drug Pharmacokinetic Parameters1**  **(90% CI)** | | |
| **Cmax** | **AUC** | **Cmin** |
| Abacavir | 300 once | 8 | ↑ 12 (↓ 1 to ↑ 26) | ⬄ | NA |
| Atazanavir2 | 400 once daily  x 14 days | 34 | ↓ 21  (↓ 27 to ↓ 14) | ↓ 25  (↓ 30 to ↓ 19) | ↓ 40  (↓ 48 to ↓ 32) |
| Atazanavir2 | Atazanavir/Ritonavir3  300/100 once daily  x 42 days | 10 | ↓ 28  (↓ 50 to ↑ 5) 3 | ↓ 25  (↓ 42 to ↓ 3) 3 | ↓ 23  (↓ 46 to ↑ 10) 3 |
| Efavirenz | 600 once daily x 14 days | 30 | ⬄ | ⬄ | ⬄ |
| Emtricitabine  (Emtriva) | 200 once daily x 7 days | 17 | ⬄ | ⬄ | ↑ 20 (↑ 12 to ↑ 29) |
| Entecavir | 1 mg once daily x 10 days | 28 | ⬄ | ↑ 13  (↓ 11 to ↑ 15) | ⬄ |
| Indinavir | 800 three times daily x 7 days | 12 | ↓ 11  (↓ 30 to ↑ 12) | ⬄ | ⬄ |
| Lamivudine | 150 twice daily  x 7 days | 15 | ↓ 24  (↓ 34 to ↓ 12) | ⬄ | ⬄ |
| Lopinavir  Ritonavir | Lopinavir/Ritonavir 400/100 twice daily x 14 days | 24 | ⬄ | ⬄ | ⬄ |
| ⬄ | ⬄ | ⬄ |
| Methadone4 | 40-110 once daily x 14 days5 | 13 | ⬄ | ⬄ | ⬄ |
| Nelfinavir M8  Metabolite | 1250 twice daily x 14 days | 29 | ⬄ | ⬄ | ⬄ |
| ⬄ | ⬄ | ⬄ |
| Oral Contraceptives6 | Ethinyl Estradiol/  Norgestimate (Ortho-Tricyclen®)  Once daily x 7 days | 20 | ⬄ | ⬄ | ⬄ |
| Ribavirin | 600 once | 22 | ⬄ | ⬄ | NA |
| Saquinavir  Ritonavir | Saquinavir/Ritonavir 1000/100 twice daily x 14 days | 32 | ↑ 22 (↑ 6 to ↑ 41) | ↑ 297 (↑ 12 to ↑ 48) | ↑ 477 (↑ 23 to ↑ 76) |
| ⬄ | ⬄ | ↑ 23 (↑ 3 to ↑ 46) |
| Tacrolimus8 | 0.05 mg/kg twice daily x 7 days | 21 | ⬄ | ⬄ | ⬄ |

1. Increase = ↑; Decrease = ↓; No Effect = ⬄; NA = Not Applicable
2. REYATAZ™ Prescribing Information (Bristol-Myers Squibb)
3. In HIV-infected patients, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and Cmin values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone (REYATAZ™ March 2004 United States Package Insert)
4. R-(active), S-and total methadone exposures were equivalent when dosed alone or with VIREAD.
5. Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.
6. Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with VIREAD.
7. Increases in AUC and Cmin are not expected to be clinically relevant; hence no dose adjustments are required when tenofovir DF and ritonavir-boosted saquinavir are coadministered.
8. Subjects received tenofovir DF 300 mg once daily as the combination product TRUVADA.

**Table 4. Drug Interactions: Pharmacokinetic Parameters for Didanosine in the Presence of VIREAD**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Didanosine1 Dose (mg)/ Method of Administration2** | **VIREAD Method of Administration2** | **N** | **% Difference (90% CI) vs. Didanosine  400 mg alone, Fasted3** | |
| **Cmax** | **AUC** |
| Buffered tablets | |  |  |  |
| 400 once daily4  x 7 days | Fasted 1 hour after didanosine | 14 | ↑ 28  (↑ 11 to ↑ 48) | ↑ 44  (↑ 31 to ↑ 59) |
| Enteric coated capsules | |  |  |  |
| 400 once,  fasted | With food, 2 hr after didanosine | 26 | ↑ 48  (↑ 25 to ↑ 76) | ↑ 48  (↑ 31 to ↑ 67) |
| 400 once,  with food | Simultaneously with didanosine | 26 | ↑ 64  (↑ 41 to ↑ 89) | ↑ 60  (↑ 44 to ↑ 79) |
| 250 once,  fasted | With food, 2 hr after didanosine | 28 | ↓ 10  (↓ 22 to ↑ 3) | ⬄ |
| 250 once,  fasted | Simultaneously with didanosine | 28 | ⬄ | ↑ 14  (0 to ↑ 31) |
| 250 once,  with food | Simultaneously with didanosine | 28 | ↓ 29  (↓ 39 to ↓ 18) | ↓ 11  (↓ 23 to ↑ 2) |

1. See PRECAUTIONS regarding use of didanosine with VIREAD.
2. Administration with food was with a light meal (~373 kcal, 20% fat).
3. Increase = ↑; Decrease = ↓; No Difference = ⬄
4. Includes 4 subjects weighing <60 kg receiving ddI 250 mg.

***Intracellular pharmacokinetics:*** In non-proliferating human peripheral blood mononuclear cells (PBMCs) *in vitro*, the half-life of tenofovir diphosphate was found to be approximately 50 hours, whereas the half-life in phytohaemagglutinin-stimulated PBMCs was found to be approximately 10 hours.

***Mechanism of action:*** Tenofovir disoproxil fumarate is a salt of an oral prodrug of tenofovir, a nucleoside monophosphate (nucleotide) analogue and obligate chain terminator with activity against HIV reverse transcriptase and HBV polymerase.

Tenofovir is converted to the active metabolite, tenofovir diphosphate, by constitutively expressed cellular enzymes through two phosphorylation reactions. This conversion occurs in both resting and activated T cells. Tenofovir diphosphate has an intracellular half-life of 10 hours in activated and 50 hours in resting peripheral blood mononuclear cells (PBMCs). Tenofovir diphosphate inhibits viral polymerases by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ. At concentrations of up to 300 μM, tenofovir shows no effect on the synthesis of mitochondrial DNA (human liver, skeletal muscle and renal proximal tubular epithelial cells) or lactic acid production (human liver and skeletal muscle cells*) in vitro*.

***Pharmacodynamic effects:*** Tenofovir has *in vitro* antiviral activity against retroviruses and hepadnaviruses.

***Anti-HIV-1 activity in vitro:***  The *in vitro* antiviral activity of tenofovir against laboratory and clinical isolates of HIV was assessed in lymphoblastoid cell lines, primary monocyte/ macrophage cells and peripheral blood lymphocytes. The IC50 (50% inhibitory concentration) for tenofovir was in the range of 0.04 µM to 8.5 µM. In drug combination studies of tenofovir with nucleoside and non-nucleoside analogue inhibitors of HIV reverse transcriptase, and protease inhibitors, additive to synergistic effects were observed. In addition, tenofovir has also been shown to be active *in vitro* against HIV‑2, with similar potency as observed against HIV‑1.

Tenofovir shows activity within three fold of wild-type IC50 against recombinant HIV-1 expressing didanosine resistance (L74V), zalcitabine resistance (T69D), or multinucleoside drug resistance (Q151M complex) mutations in reverse transcriptase. Tenofovir shows slightly increased activity against HIV-1 expressing the abacavir/lamivudine resistance mutation M184V. The activity of tenofovir against HIV-1 strains with thymidine analog-associated mutations (thymidine-associated mutations) appears to depend on the type and number of these resistance mutations. In the presence of mutation T215Y, a twofold increase of the IC50 was observed. In 10 samples which had multiple thymidine-associated mutations (mean 3.4), a mean 3.7-fold increase of the IC50 was observed (range 0.8 to 8.4). There are insufficient data at this time to correlate specific thymidine-associated mutation patterns with reduced susceptibility to tenofovir.

Multinucleoside resistant HIV-1 with T69S double insertions have reduced susceptibility to tenofovir (IC50 >10-fold compared with wild type). Tenofovir shows activity against non-nucleoside reverse transcriptase inhibitor resistant HIV-1 with K103N or Y181C mutations. Cross-resistance to protease inhibitor resistance mutations is not expected due to the different viral enzymes targeted.

Strains of HIV-1 with reduced susceptibility to tenofovir have been selected *in vitro*. The selected viruses express a K65R mutation in RT and showed 3 to 4-fold reduced susceptibility to tenofovir. The K65R mutation in RT can also be selectedby zalcitabine, didanosine, and abacavir, and causes reduced susceptibility to zalcitabine, didanosine, stavudine (d4T), abacavir, and lamivudine (14-, 4-, 2-, 3-, and 25-fold, respectively).

***Anti-Hepatitis B Virus Activity In Vitro:*** The *in vitro* antiviral activity of tenofovir against laboratory strains and clinical isolates of HBV was assessed in HepG2 cells.  The EC50 values for tenofovir were in the range 0.06 to 1.5 µM.  Tenofovir diphosphate inhibits recombinant HBV polymerase with a Ki (inhibition constant) of 0.18 µM. In *in vitro* drug combination studies of tenofovir with nucleoside anti-HBV reverse transcriptase inhibitors lamivudine, telbivudine and entecavir, additive anti-HBV activity was observed. Additive to slight synergistic effects were observed with the combination of tenofovir and emtricitabine.

**CLINICAL TRIALS**

***Clinical efficacy in HIV Infection:***

The demonstration of benefit of VIREAD is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in controlled studies of VIREAD in treatment-naïve adults and in treatment-experienced adults.

***Treatment-Experienced Adult Patients***

**Study 907: VIREAD + Standard Background Therapy (SBT) Compared to Placebo + SBT**

Study 907 was a 24 week, double-blind placebo-controlled multicentre study of VIREAD added to a stable background regimen of antiretroviral agents in 550 treatment-experienced patients. After 24 weeks of blinded study treatment, all patients continuing on study were offered open-label VIREAD for an additional 24 weeks. Patients had a mean baseline CD4 cell count of 427 cells/mm3 (range 23–1385), median baseline plasma HIV-1 RNA of 2340 (range 50–75,000) copies/mL, and mean duration of prior HIV-1 treatment was 5.4 years. Mean age of the patients was 42 years, 85% were male and 69% were Caucasian, 17% Black and 12% Hispanic.

Changes from baseline in log10 copies/mL plasma HIV-1 RNA levels over time up to week 48 are presented below in Figure 1.



The percent of patients with HIV-1 RNA <400 copies/mL and outcomes of patients through 48 weeks are summarised in Table 5.

**Table 5. Outcomes of Randomised Treatment (Study 907)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcomes** | **0-24 weeks** | | **0-48 weeks** | **24-48 weeks** |
| **VIREAD** **(N=368)**  **%**  **(95% CI)** | **Placebo** **(N=182)**  **%**  **(95% CI)** | **VIREAD** **(N=368)**  **%** | **Placebo Crossover to VIREAD**  **(N=170)**  **%** |
| HIV-1 RNA <400 copies/mL1 | 40%4  (35% to 45%) | 11%4  (6% to 16%) | 28% | 30% |
| Virologic failure2 | 53% | 84% | 61% | 64% |
| Discontinued due to adverse event | 3% | 3% | 5% | 5% |
| Discontinued for other reasons3 | 3% | 3% | 5% | 1% |

1. Patients with HIV-1 RNA <400 copies/mL and no prior study drug discontinuationat Week 24 and 48 respectively.
2. Patients with HIV-1 RNA ≥400 copies/mL efficacy failure or missing HIV –1 RNA at Week 24 and 48 respectively.
3. Includes lost to follow up, patient withdrawal, non-compliance, protocol violation and other reasons.
4. Difference 29% p < 0.001

At 24 weeks of therapy, there was a higher proportion of patients in the VIREAD arm compared to the placebo arm with HIV-1 RNA <50 copies/mL (19% and 1%, respectively). Mean change in absolute CD4 counts by week 24 was +11 cells/mm3 for the VIREAD group and -5 cells/mm3 for the placebo group. Mean change in absolute CD4 counts by week 48 was +4 cells/mm3 for the VIREAD group.

***Treatment-Experienced Paediatric Patients 12 Years of Age and Older***

In study GS-US-104-0321 (study 321), 87 treatment-experienced patients 12 to <18 years of age were treated with VIREAD (n=45) or placebo (n=42) in combination with an optimized background regimen (OBR) for 48 weeks. The mean baseline CD4 cell count was 374 cells/mm3 and the mean baseline plasma HIV-1 RNA was 4.6 log10 copies/mL. The median DAVG24 and DAVG48 in plasma HIV-1 RNA were -1.58 and -1.42 log10 copies/mL for the VIREAD treatment group compared to -1.55 and -1.35 log10 copies/mL for the placebo group at weeks 24 and 48, respectively. Overall, the trial failed to show a difference in virologic response between the two treatment groups. Subgroup analyses suggest the lack of difference in virological response may be attributable to imbalances between treatment arms in baseline viral susceptibility to VIREAD and OBR. In patients with partially active or non-active OBR (genotypic sensitivity score ≤ 1), the addition of VIREAD or placebo resulted in a median DAVG24 in plasma HIV RNA of -1.66 and -1.14 log10 copies/mL, respectively. Although changes in HIV-1 RNA in these highly treatment experienced patients were less than anticipated, the comparability of the pharmacokinetic and safety data to that observed in adults supports the use of VIREAD in paediatric patients ≥ 12 years of age who weigh ≥ 35 kg whose HIV-1 isolate is expected to be sensitive to VIREAD.

HIV-1 isolates from 43 patients who had plasma HIV-1 RNA ≥ 400 copies/mL were evaluated for tenofovir resistance-associated substitutions. One patient developed the K65R substitution by week 48.

Treatment-Naïve Adult Patients

**Study 903: VIREAD + Lamivudine +Efavirenz Compared to Stavudine + Lamivudine + Efavirenz**

Data through 144 weeks are reported for Study 903, a double-blind, active-controlled multicentre study comparing VIREAD (300 mg once daily) administered in combination with lamivudine and efavirenz versus d4T, lamivudine, and efavirenz in 600 antiretroviral-naïve patients. Patients had a mean age of 36 years (range 18–64), 74% were male, 64% were Caucasian and 20% were Black. The mean baseline CD4 cell count was 279 cells/mm3 (range 3–956) and median baseline plasma HIV-1 RNA was 77,600 copies/mL (range 417–5,130,000). Patients were stratified by baseline HIV-1 RNA and CD4 count. Forty-three percent of patients had baseline viral loads >100,000 copies/mL and 39% had CD4 cell counts <200 cells/mm3. Treatment outcomes through 144 weeks are presented in Table 6 below.

Table 6. Outcomes of Randomised Treatment (Study 903)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Outcomes | At Week 48 | | At Week 144 | |
| VIREAD+ 3TC+EFV (N=299) | d4T +3TC+EFV (N=301) | VIREAD+ 3TC+EFV (N=299) | d4T +3TC+EFV (N=301) |
| % | % | % | % |
| Responder1 | 79%4 | 82%4 | 68%5 | 62%5 |
| Virologic failure2 | 6% | 4% | 10% | 8% |
| Rebound | 5% | 3% | 8% | 7% |
| Never suppressed | 0% | 1% | 0% | 0% |
| Added an antiretroviral agent | 1% | 1% | 2% | 1% |
| Death | <1% | 1% | <1% | 2% |
| Discontinued due to adverse event | 6% | 6% | 8% | 13% |
| Discontinued for other reasons3 | 8% | 7% | 14% | 15% |

1. Patients achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Week 48 and 144.
2. Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Week 48 and 144.
3. Includes lost to follow-up, patient’s withdrawal, non-compliance, protocol violation and other reasons.
4. Difference -3.0% (-9.2% to 3.1%) p=0.48. The difference and confidence interval are stratum weighted on baseline HIV-1 RNA and CD4.
5. Difference 6.1% (-1.4% to 13.7%) p=0.11. The difference and confidence interval are stratum weighted on baseline HIV-1 RNA and CD4.

Achievement of plasma HIV-1 RNA concentrations of less than 400 copies/mL at week 144 was similar between the two treatment groups for the population stratified at baseline on the basis of HIV-1 RNA concentration (≤ or >100,000 copies/mL) and CD4 cell count (< or ≥200 cells/mm3). Through 144 weeks of therapy, 62% and 58% of patients in the VIREAD and d4T arms, respectively achieved and maintained confirmed HIV-1 RNA <50 copies/mL. The mean increase from baseline in CD4 cell count was 263 cells/mm3 for the VIREAD arm and 283 cells/mm3 for the d4T arm.

The percentage of patients who achieved and maintained confirmed HIV RNA <400 using intent-to-treat analysis through 144 weeks of treatment in study 903 is presented in Figure 2 below.

Genotypic analyses of patients with virologic failure showed development of efavirenz-associated and lamivudine-associated mutations to occur most frequently and with no difference between the treatment arms. The K65R mutation occurred in 8 patients on the VIREAD arm and in 2 patients on the d4T arm. Of the 8 patients who developed K65R in the VIREAD arm through 144 weeks, 7 of these occurred in the first 48 weeks of treatment and the last one at week 96. Among these patients, 5/8 patients subsequently gained full virologic control (<50 copies/mL) upon switching to new regimens that included a protease inhibitor in combination with nucleoside reverse transcriptase inhibitors through a median of 155 weeks of follow-up. From both genotypic and phenotypic analyses there was no evidence for other pathways of resistance to VIREAD.

**Figure 2   
Percentage of patients with HIV RNA < 400 using Intent-to-treat analysis   
through Week 144: Study 903   
(Missing=Failure, Switch=Failure)**



**Study 934: VIREAD + EMTRIVA + Efavirenz Compared with Combivir® (lamivudine / zidovudine) + Efavirenz**

Study 934 is a randomized, open-label, active controlled multicentre study comparing two different dosing regimens in 511 antiretroviral-naïve HIV-1 infected patients. Patients were randomised to receive either EMTRIVA + VIREAD administered in combination with efavirenz or Combivir (lamivudine/zidovudine) administered in combination with efavirenz. For patients randomised to receive EMTRIVA + VIREAD the two drugs were administered individually for the first 96 weeks and then switched to TRUVADA (fixed dose combination of tenofovir DF 300 mg/emtricitabine 200 mg) during weeks 96 to 144, without regard to food.

For inclusion in the study, antiretroviral treatment naïve adult patients (≥ 18 years) with plasma HIV RNA greater than 10,000 copies/mL, must have an estimated glomerular filtration rate as measured by Cockroft-Gault method of ≥ 50 mL/min, adequate haematologic function, hepatic transaminases and alanine aminotransferases ≤ 3 ULN, total bilirubin ≤ 1.5 mg/dL, serum amylase ≤ 1.5 ULN and serum phosphorus ≥ 2.2 mg/dL. Exclusion criteria included: a new AIDS defining condition diagnosed within 30 days (except on the basis of CD4 criteria), ongoing therapy with nephrotoxic drugs or agents that interacted with efavirenz, pregnancy/lactation, a history of clinically significant renal / bone disease or malignant disease other than Kaposi’s sarcoma or basal-cell carcinoma, or a life expectancy of less than one year. If efavirenz-associated central nervous system toxicities occurred, nevirapine could be substituted for efavirenz. Patients who were not receiving their originally assigned treatment regimen after week 48 or 96 and during the 30-day extension study window were not eligible to continue to weeks 96 or 144 respectively.

Patients had a mean age of 38 years (range 18 to 80), 86% were male, 59% were Caucasian and 23% were Black. The mean baseline CD4 cell count was 245 cells/mm3 (range 2 to 1191) and median baseline plasma HIV-1 RNA was 5.01 log10 copies/mL (range 3.56 to 6.54). Patients were stratified by baseline CD4 count (< or ≥ 200 cells/mm3); 41% had CD4 cell counts <200 cells/mm3 and 51% of patients had baseline viral loads >100,000 copies/mL Treatment outcomes at 48 and 144 weeks for those patients who did not have efavirenz resistance at baseline are presented in Table 7.

**Table 7 Outcomes of Randomised Treatment at Weeks 48 and 144 (Study 934) in Treatment Naïve Patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome at Weeks 48 and 144** | **WEEK 48** | | **WEEK 144** | |
| **VIREAD + EMTRIVA+EFV**  **(N=244)** | **Combivir**  **+ EFV**  **(N=243)** | **TRUVADA4 + EFV**  **(N=227)** | **Combivir + EFV**  **(N=229)** |
| Responder1 | 84% | 73% | 71% | 58% |
| Virologic failure2 | 2% | 4% | 3% | 6% |
| Rebound | 1% | 3% | 2% | 5% |
| Never suppressed | 0% | 0% | 0% | 0% |
| Change in antiretroviral regimen | 1% | 1% | 1% | 1% |
| Death3 | <1% | 1% | 1% | 1% |

1. Patients achieved and maintained confirmed HIV-1 RNA <400 copies/mL.

2. Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL.

3. All deaths were unrelated to study drugs.

4. Patients received VIREAD + EMTRIVA up to week 96 and switched to TRUVADA from week 96 to 144.

In this study, VIREAD + EMTRIVA in combination with efavirenz was statistically significantly superior to Combivir in combination with efavirenz with regards to the primary and secondary endpoints: achieving and maintaining HIV-1 RNA < 400 copies/mL through 48 and 144 weeks (Table 7). The difference in the proportions of responders between the VIREAD + EMTRIVA group and the Combivir group was 11.4%, and the 95% CI was 4.3% to 18.6% (p=0.002) at week 48 and a difference of 12.9% (95% CI was 4.2% to 21.6%, p=0.004) at week 144.

Through 48 weeks of therapy, 80% and 70% of patients in the VIREAD + EMTRIVA and the Combivir arms, respectively, achieved and maintained HIV-1 RNA <50 copies/mL. The difference in the proportions of responders between the VIREAD + EMTRIVA group and the Combivir group was 9.1%, and the 95% CI was 1.6% to 16.6% (p=0.021) at week 48. The proportion of patients responding at 144 weeks of therapy was higher in the TRUVADA group (64%) compared with the Combivir group (56%); p=0.082, a difference of 8.1% and the 95% CI was -0.8% to 17.0%.

The mean increase from baseline in CD4 cell count was 190 cells/mm3 and 312 cells/mm3 for the VIREAD + EMTRIVA + efavirenz arm, and 158 cells/mm3 and 271 cells/mm3for the Combivir + efavirenz arm (p=0.002 and p = 0.088) at weeks 48 and 144 respectively.

Resistance analysis was performed on HIV isolates from all patients with > 400 copies/mL of HIV-1 RNA at week 144 while on study drug or after treatment switch. Genotypic resistance to efavirenz, predominantly the K103N mutation, was the most common form of resistance that developed in both treatment groups. Resistance to efavirenz occurred in 68% (13/19) analysed patients in the TRUVADA group and in 72% (21/29) analysed patients in the Combivir group. The M184V mutation, associated with resistance to emtricitabine and lamivudine, developed significantly less in the analysed patients in the TRUVADA group 11% (2/19) compared with the analysed patients in the Combivir group, 34% (10/29). Two patients in the Combivir group developed thymidine analog mutations, specifically D67N or K70R mutations in the reverse transcriptase gene. No patient in either treatment group developed the K65R mutation, which is associated with reduced susceptibility to VIREAD.

**Genotypic Analyses of VIREAD in Patients with Previous Antiretroviral Therapy (Study 902 and 907)**

The virologic response to VIREAD therapy has been evaluated with respect to baseline viral genotype (N=222) in treatment experienced patients participating in trials 902 and 907. In both of these studies, 94% of the participants evaluated had baseline HIV isolates expressing at least one NRTI mutation. These included resistance mutations associated with zidovudine (M41L, D67N, K70R, L210W, T215Y/F or K219Q/E/N), the lamivudine/abacavir-associated mutation (M184V), and others. In addition the majority of participants evaluated had mutations associated with either PI or NNRTI use. Virologic responses for patients in the genotype substudy were similar to the overall results in studies 902 and 907.

Several exploratory analyses were conducted to evaluate the effect of specific mutations and mutational patterns on virologic outcome. Descriptions of numerical differences in HIV RNA response are displayed in Table 8. Because of the large number of potential comparisons, statistical testing was not conducted.

Varying degrees of cross-resistance to VIREAD from pre-existing zidovudine-associated mutations were observed and appeared to depend on the number and type of mutations. VIREAD-treated patients whose HIV expressed 3 or more zidovudine-associated mutations that included either the M41L or L210W reverse transcriptase mutation showed reduced responses to VIREAD therapy; however, these responses were still improved compared with placebo. The presence of the D67N, K70R, T215Y/F or K219Q/E/N mutation did not appear to affect responses to VIREAD therapy. The HIV RNA responses by number and type of baseline zidovudine-associated mutations are shown in Table 8.

Table 8. HIV RNA Response at Week 24 by Number of Baseline Zidovudine-Associated Mutations in Studies 902 and 907 (Intent-To-Treat)1

|  |  |  |
| --- | --- | --- |
| **Number of baseline**  **zidovudine-associated mutations2** | **Change in HIV RNA3  (N)** | |
| **VIREAD** | **Placebo** |
| None | -0.80 (68) | -0.11 (29) |
| Any | -0.50 (154) | 0 (81) |
| 1 – 2 | -0.66 (55) | -0.04 (33) |
| > 3 including M41L or L210W | -0.21 (57) | +0.01 (29) |
| > 3 without M41L or L210W | -0.67 (42) | +0.07 (19) |

1. Genotypic testing performed by Virco Laboratories and Visible Genetics TruGeneTM technology
2. M41L, D67N, K70R, L210W, T215Y/F or K219Q/E/N in RT
3. Average HIV RNA change from baseline through week 24 (DAVG24) in log10 copies/mL

In the protocol defined analyses, virologic response to VIREAD was not reduced in patients with HIV that expressed the lamivudine/ abacavir-associated M184V mutation. In the absence of zidovudine-associated mutations, patients with the M184V mutation receiving VIREAD showed a –0.84 log10 copies/mL decrease in their HIV RNA relative to placebo. In the presence of zidovudine-associated mutations, the M184V mutation did not affect the mean HIV RNA responses to VIREAD treatment. HIV-1 RNA responses among these patients were durable through week 48.

There were limited data on patients expressing some primary nucleoside reverse transcriptase inhibitor mutations and multi-drug resistant mutations at baseline. However, patients expressing mutations at K65R (N=6), or L74V without zidovudine-associated mutations (N=6) appeared to have reduced virologic responses to VIREAD.

The presence of at least one HIV protease inhibitor or non-nucleoside reverse transcriptase inhibitor mutation at baseline did not appear to affect the virologic response to VIREAD. Cross-resistance between VIREAD and HIV protease inhibitors is unlikely because of the different enzyme targets involved.

**Phenotypic Analyses of VIREAD in Patients with Previous Antiretroviral Therapy (Study 902 and 907)**

The virologic response to VIREAD therapy has been evaluated with respect to baseline phenotype (N=100) in treatment experienced patients participating in trials 902 and 907. Phenotypic analysis of baseline HIV from patients in Studies 902 and 907 demonstrated a correlation between baseline susceptibility to VIREAD and response to VIREAD therapy. Table 9 summarises the HIV RNA response by baseline VIREAD susceptibility.

Table 9. HIV RNA Response at Week 24 by Baseline VIREAD Susceptibility in Studies 902 and 907 (Intent-To-Treat)1

|  |  |
| --- | --- |
| Baseline VIREAD Susceptibility2 | Change in HIV RNA3 (N) |
| < 1  > 1 and < 3  > 3 and < 4 | -0.74 (35)  -0.56 (49)  -0.3 (7) |
| < 4  > 4 | -0.61 (91)  -0.12 (9) |

1. Tenofovir susceptibility was determined by recombinant phenotypic AntivirogramTM assay (Virco)

2. Fold change in susceptibility from wild-type

3. Average HIV RNA change from baseline through week 24 (DAVG24) in log10 copies/mL

***Clinical efficacy in chronic hepatitis B:***

The demonstration of benefit of VIREAD is based on histological, virological, biochemical, and serological responses in adults with HBeAg positive and HBeAg negative chronic hepatitis B with compensated and decompensated liver function; clinical evidence of prior treatment failure; and patients co-infected with HIV-1 and HBV. In these clinical studies patients had active viral replication at baseline. VIREAD has demonstrated anti-HBV activity in patients with HBV containing lamivudine- or adefovir-resistance-associated mutations.

**Study 0102 and 0103: VIREAD Compared with HEPSERA (adefovir dipivoxil)**

Results through 48 weeks from two randomised, phase 3 double‑blind studies comparing VIREAD to HEPSERA in patients with compensated liver disease are presented in Table 10 below. Study GS-US-174-0103 (0103) was conducted in 266 (randomised and treated) HBeAg positive patients while study GS-US-174-0102 (0102) was conducted in 375 (randomised and treated) patients negative for HBeAg and positive for HBeAb.

In both of these studies VIREAD was statistically significantly superior to HEPSERA for the primary efficacy endpoint of complete response, (defined as HBV DNA levels < 400 copies/ml and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score). Treatment with VIREAD 300 mg was also associated with significantly greater proportions of patients with HBV DNA < 400 copies/ml, when compared to HEPSERA 10 mg treatment. Both treatments produced similar results with regard to histological response (defined as Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score) at Week 48 (see Table 10 below).

In study 0103 a significantly greater proportion of patients in the VIREAD group than in the HEPSERA group had normalized ALT and achieved HBsAg loss at Week 48 (see Table 10 below).

Table 10. Clinical Outcomes of Randomised Treatment (Study 0102 and 0103) at Week 48

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Study 0102  (HBeAg Negative) | | Study 0103  (HBeAg Positive) | |
| **Parameter** | **VIREAD**  **n= 250** | **HEPSERA**  **n= 125** | **VIREAD**  **n= 176** | **HEPSERA**  **n= 90** |
| **Complete Response** (%) 1 | 71\* | 49 | 67\* | 12 |
| **Histology** |  |  |  |  |
| Histological Response (%) 2 | 72 | 69 | 74 | 68 |
| **HBV DNA** (%)  < 400 copies/ml (<69 IU/ml) | 93\* | 63 | 76\* | 13 |
| **ALT** (%) |  |  |  |  |
| Normalized ALT 3 | 76 | 77 | 68\* | 54 |
| **Serology** (%)  HBeAg Loss/Seroconversion | N/A | N/A | 22/21 | 18/18 |
| HBsAg Loss/Seroconversion | 0/0 | 0/0 | 3\*/1 | 0/0 |

\*p value vs HEPSERA < 0.05.

1 Complete response defined as HBV DNA levels < 400 copies/ml and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.

2 Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.

3The population used for analysis of ALT normalization included only patients with ALT above ULN at baseline.

VIREAD was associated with statistically significantly greater proportions of patients with undetectable HBV DNA (< 169 copies/ml [< 29 IU/ml]; the limit of quantification of the Roche Cobas TaqMan HBV assay), when compared to HEPSERA (study 0102; 91%, 56% and study 0103; 69%, 9%) respectively.

Response to treatment with VIREAD was comparable in nucleoside-experienced (n=51) and nucleoside-naïve (n=375) patients and in patients with normal ALT (n=21) and abnormal ALT (n=405) at baseline when studies 0102 and 0103 were combined. Forty-nine of the 51 nucleoside-experienced patients were previously treated with lamivudine. Seventy-three percent of nucleoside-experienced and 69% of nucleoside-naïve patients achieved complete response to treatment; 90% of nucleoside-experienced and 88% of nucleoside-naïve patients achieved HBV DNA suppression < 400 copies/ml. All patients with normal ALT at baseline and 88% of patients with abnormal ALT at baseline achieved HBV DNA suppression < 400 copies/ml.

**Treatment Beyond 48 weeks (Studies 0102 and 0103):**

In studies 0102 and 0103, after receiving double-blind treatment for 48 weeks (either VIREAD or HEPSERA), patients rolled over with no treatment interruption, to open-label VIREAD.

In study 0102, 304 of 375 patients (81%) continued through week 240, while in study 0103, 185of 266 (70%) continued through week 240. At weeks 96, 144, 192 and 240 viral suppression, biochemical and serological responses were maintained with continued VIREAD treatment (see Table 11 below).

**Table 11. Virological, Biochemical and Serological Response at Weeks 96, 144, 192 and 240 (Study 0102 and 0103)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcomesa** | Study 0102  (HBeAg Negative) | | | | | | | | Study 0103  **(HBeAg Positive)** | | | | | | | |
|  | **VIREAD**  **(n= 250)** | | | | **HEPSERA Rollover to VIREAD**  **(n= 125)** | | | | **VIREAD**  **(n= 176)** | | | | **HEPSERA Rollover to VIREAD**  **(n= 90)** | | | |
| **Week** | **96 b** | **144e** | **192 h** | **240j** | **96 c** | **144 f** | **192 i** | **240k** | **96 b** | **144 e** | **192 h** | **240 j** | **96 c** | **144 f** | **192 i** | **240 k** |
| **HBV DNA** (%)  < 400 copies/mL (<69 IU/mL) | 90 | 87 | 84 | 83 | 89 | 88 | 87 | 84 | 76 | 72 | 68 | 64 | 74 | 71 | 72 | 66 |
| **HBV DNA** (%)  < 169 copies/ml (<29 IU/mL) | 89 | 86 | 83 | 82 | 89 | 88 | 87 | 84 | 73 | 70 | 68 | 63 | 74 | 70 | 70 | 66 |
| **ALT** (%)  Normalised ALT d | 72 | 73 | 67 | 70 | 68 | 70 | 77 | 76 | 60 | 55 | 56 | 46 | 65 | 61 | 59 | 56 |
| **Serology** (%)  HBeAg Loss/ Seroconversion | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 26/23 | 29/23 | 34/25 | 38/30 | 24/20 | 33/26 | 36/30 | 38/31 |
| HBsAg Loss/ Seroconversion | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0l | 5/4 | 8/6g | 11/8g | 11/8m | 6/5 | 8/7g | 8/7g | 10/10m |

a Based upon Long-Term Evaluation Algorithm (LTE Analysis) – Patients who discontinued the study at any time prior to week 240 due to a protocol defined endpoint, as well as those completing week 240, are included in the denominator,

b 48 weeks double-blind VIREAD followed by up to 48 weeks open-label,

c 48 weeks double-blind HEPSERA followed by up to 48 weeks open-label VIREAD,

d The population used for analysis of ALT normalisation included only patients with ALT above ULN at baseline,

e 48 weeks double-blind VIREAD followed by 96 weeks open-label,

f 48 weeks double-blind HEPSERA followed by 96 weeks open-label VIREAD,

g Figures presented are cumulative percentages based upon a Kaplan Meier analysis (KM-ITT),

h 48 weeks double-blind VIREAD followed by 144 weeks open-label,

i 48 weeks double-blind HEPSERA followed by 144 weeks open-label VIREAD,

j 48 weeks double‑blind VIREAD followed by 192 weeks open‑label.

k48 weeks double‑blind HEPSERA followed by 192 weeks open‑label VIREAD.

l One patient in this group became HBsAg negative for the first time at the 240 week visit and was ongoing in the study at the time of the data cut-off. However, the subject’s HBsAg loss was ultimately confirmed at the subsequent visit.

m Figures presented are cumulative percentages based upon a Kaplan Meier analysis excluding data collected after the addition of emtricitabine to open‑label VIREAD (KM‑TDF).

n/a = Not Applicable

Patients with HBV DNA≥400 copies/mL at week 72 or later were eligible to receive intensification therapy with open-label TRUVADA (tenofovir DF/emtricitabine) and results from these patients are not included as responders in this table (intensification therapy = failure). Results from the VIREAD 240 week treatment groups including these patients were 83% and 70% for HBV DNA < 400 copies/mL and 71% and 51% for normalised ALT, for study 0102 and 0103 respectively; and 39%/31% for HBeAg loss/seroconversion (study 0103 only).

Paired baseline and week 240 liver biopsy data were available for 331/489 patients who remained in studies 0102 and 0103 (see Table 12 below). Ninety-five percent (225/237) of patients without cirrhosis at baseline and 99% (93/94) of patients with cirrhosis at baseline had either no change or an improvement in fibrosis (Ishak fibrosis score). Of the 94 patients with cirrhosis at baseline (Ishak fibrosis score 5‑6), 26% (24) experienced no change in Ishak fibrosis score and 72% (68) experienced regression of cirrhosis by week 240 with a reduction in Ishak fibrosis score of at least 2 points.

Table 12: Histological response (%) in compensated HBeAg negative and HBeAg positive subjects at week 240 compared to baseline

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Study 0102  (HBeAg negative) | | Study 0103  (HBeAg positive) | |
| **VIREAD**  n = 250c | **HEPSERA Rollover to VIREAD**  n = 125d | **VIREAD**  n = 176c | **HEPSERA Rollover to VIREAD**  n = 90d |
| Histological responsea,b (%) | 88  [130/148] | 85  [63/74] | 90  [63/70] | 92  [36/39] |

a The population used for analysis of histology included only patients with available liver biopsy data (Missing = Excluded) by week 240. Response after addition of emtricitabine is excluded (total of 17 subjects across both studies).

b Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.

c 48 weeks double-blind VIREAD followed by up to 192 weeks open-label.


d 48 weeks double-blind HEPSERA followed by up to 192 weeks open-label VIREAD

When the data were evaluated including only patients that completed 240 weeks of therapy (observed (missing data is excluded) and data after the addition of emtricitabine included; on-therapy analysis), in the group of patients who received 48 weeks of double-blind treatment with VIREAD followed by open-label treatment with VIREAD; 99% and 96% of patients had HBV DNA < 400 copies/mL and 85 (155/183)% and 69 (71/103)% of patients had ALT normalisation at week 240, in studies 0102 and 0103 respectively. In study 0103, 50 (52/104)%/40 (41/103)% of patients experienced HBeAg loss/seroconversion, 11% of patients experienced HBsAg loss and 8% of patients experienced HBsAg seroconversion by week 240.

Similarly (using the on-therapy analysis), in the group of patients who received 48 weeks of double-blind treatment with HEPSERA followed by open-label treatment with VIREAD; 99 (99/100)% and 100 (64/64)% of patients had HBV DNA < 400 copies/mL and 86% and 80% of patients had ALT normalisation, at week 240, in studies 0102 and 0103 respectively. In study 0103, 48%/41% of patients experienced HBeAg loss/seroconversion, 10% of patients experienced HBsAg loss and 10% of patients experienced HBsAg seroconversion, while on VIREAD.

The proportion of patients in studies 0102 and 0103 with HBV DNA < 400 copies/mL are shown in Figures 3 and 4.

**Figure 3 Proportion of Patients with HBV DNA <400 copies/mL by Visit (Study 0102)**




Randomised and treated patients, LTE Algorithm; 240 week data is also reported in Table 11.

TDF: 48 weeks double-blind VIREAD followed by up to 192 weeks open-label

ADV: 48 weeks double-blind HEPSERA followed by up to 192 weeks open-label VIREAD.

**Figure 4 Proportion of Patients with HBV DNA <400 copies/mL by Visit (Study 0103)**



Randomised and treated patients, LTE Algorithm; 240 week data is also reported in Table 11.

TDF: 48 weeks double-blind VIREAD followed by up to 192 weeks open-label

ADV: 48 weeks double-blind HEPSERA followed by up to 192 weeks open-label VIREAD.

**Experience with Patients Co-infected with HIV and HBV (Study ACTG 5127)**

In a randomized, 48 week double-blind, non-inferiority trial, VIREAD (TDF) 300 mg daily was compared with HEPSERA (ADV) 10 mg daily in the treatment of chronic hepatitis B patients who were co-infected with HIV and were stable on antiretroviral therapy. Mean baseline serum HBV DNA were 9.45 log10 copies/ml and 8.85 log10 copies/ml in subjects randomised to TDF (n=27) and ADV (n=25), respectively. In subjects for whom there was week 48 data (n=35), the mean change from baseline in serum HBV DNA was -5.74 log10 copies/ml for the TDF group (n=18) and -4.03 log10 copies/ml for the ADV group (n=17), respectively. A total of 61 % of subjects (36% in the TDF group and 25% in the ADV group) had normalised serum ALT at week 48, but the differences were not statistically significant. The study showed that over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA and TDF was not inferior to ADV in HBV viral suppression.

**Experience in Patients who had Incomplete Viral Response to HEPSERA (Study 0106)**

The efficacy and safety of VIREAD 300 mg or TRUVADA (tenofovir DF/emtricitabine) is being evaluated in a randomised, double-blind study (Study GS-US-174-0106, 0106), in HBeAg positive and HBeAg negative patients who had persistent viraemia (HBV DNA ≥ 1000 copies/ml) while receiving HEPSERA 10 mg for more than 24 weeks. Overall at Week 48, treatment with VIREAD resulted in 66% (35/53) of patients with HBV DNA < 400 copies/ml and 64% (34/53) of patients with undetectable HBV DNA (below 169 copies/ml the limit of quantification of the Roche Cobas TaqMan HBV assay); patients that discontinued prior to 48 weeks, including those who received intensification therapy (TRUVADA (tenofovir DF/emtricitabine) were excluded. In addition, at Week 48, the percentage of patients who had ALT normalisation was 33% (9/27).

In study 0106, patients were also analysed based upon lamivudine- or adefovir-resistant HBV results at baseline; patients that discontinued prior to 48 weeks were considered as failures. Table 13 below summarizes Week 48 results of patients treated with VIREAD.

**Table 13. Summary of Clinical Efficacy at Week 48 (Study 0106): RAT Analysis Set**

|  |  |
| --- | --- |
|  | **VIREAD**  **(n=53)** |
| **HBV DNA < 400 copies/mL, n(%)1** | **43 (81%)** |
| Lamivudine-resistant patients, n/N (%)1 | 6/7 (86%) |
| Adefovir-resistant patients, n/N (%)1 | 7/8 (88%) |
| **HBV DNA < 169 copies/mL1** | **40 (76%)** |
| Lamivudine-resistant patients, n/N (%)1 | 5/7 (72%) |
| Adefovir-resistant patients, n/N (%)1 | 7/8 (88%) |
| **Normalised ALT1, 2** | **11/27 (41%)** |
| Lamivudine-resistant patients, n/N (%)1 | 3/4 (75%) |
| Adefovir-resistant patients, n/N (%)1 | 3/5 (60%) |
| **HBeAg Loss1, 3** | **3/38 (8%)** |
| **HBeAg Seroconversion1, 3** | **2/38 (5%)** |
| **HBsAg Loss1, 3** | **1/53 (2%)** |
| **HBsAg Seroconversion1, 3** | **1/53 (2%)** |

1 Patients who prematurely discontinued the study prior to week 48 were considered failures at all time points following the time

of discontinuation.

2 Normalised ALT defined as ALT at or below the ULN, for subjects with above the ULN at baseline.

3 HBeAg/HBsAg loss defined as HBeAg/HBsAg result for those subjects with positive HBeAg/HBsAg at baseline.

Seroconversion defined as HBeAg/HBsAg loss and positive anti-HBe/anti-HBs result.

At week 48, no patient with lamivudine- or adefovir-resistant mutations at baseline, had HBeAg/HBsAg loss and/or seroconversion.

**Experience in Patients with Decompensated Liver Disease (Study 0108)**

Study GS-US-174-0108 (0108) is a randomized, double-blind, active controlled study evaluating the safety and efficacy of VIREAD (n=45) for 48 weeks in patients with decompensated liver disease. In the VIREAD treatment arm, patients had a mean Child-Pugh-Turcotte (CPT) score of 7.2, mean HBV DNA of 5.8 log10 copies/mL and mean serum ALT of 61 U/L at baseline. Forty-two percent (19/45) of patients had at least 6 months of prior lamivudine experience and 9 of 45 patients (20%) had lamivudine and/or adefovir resistance substitutions at baseline. The coprimary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dL or confirmed decrease in serum phosphorus of < 2 mg/dL.

In the VIREAD treatment arm, 3 of 45 patients (7%) discontinued treatment due to an adverse event; 4 of 45 (9%) experienced a confirmed increase in serum creatinine of ≥ 0.5 mg/dL or confirmed decrease in serum phosphorus of < 2 mg/mL through week 48; these results were similar to those in the non-VIREAD containing treatment arm. HBV DNA < 400 copies/mL and normal ALT were observed in 31 of 44 patients (70%) and 25 of 44 patients (57%), respectively, in the VIREAD treatment arm. The mean change from baseline in CPT score was -0.8; the mean absolute CPT score was 6 at week 48.

**Experience in Paediatric Patients 12 Years of Age and Older (Study 0115)**

In Study GS-US-174-0115 (0115), 106 HBeAg negative and positive patients aged 12 to < 18 years with chronic HBV infection [HBV DNA ≥105 copies/ml, elevated serum ALT (≥2 x ULN) or a history of elevated serum ALT levels in the past 24 months] were treated with VIREAD (n=52) or placebo (n=54) for 72 weeks. At Week 72, 88% (46/52) of patients in the VIREAD treatment group and 0% (0/54) of patients in the placebo group had HBV DNA < 400 copies/mL. Seventy-four percent (26/35) of patients in the VIREAD group had normalised ALT at Week 72 compared to 31% (13/42) in the placebo group. Response to treatment with VIREAD was comparable in nucleos(t)ide-naïve patients (n=20) and nucleos(t)ide-experienced (n=32) patients. Ninety-five percent of nucleos(t)ide-naïve patients and 84% nucleos(t)ide-experienced patients achieved HBV DNA < 400 copies/mL at Week 72. At week 72, 96% (27/28) of immune-active patients (HBV DNA ≥105 copies/ml, serum ALT > 1.5 x ULN) in the tenofovir disoproxil fumarate treatment group and 0% (0/32) of patients in the placebo group had HBV DNA < 400 copies/ml. Seventy-five percent (21/28) of immune-active patients in the tenofovir disoproxil fumarate group had normal ALT at week 72 compared to 34% (11/32) in the placebo group.

**Clinical Resistance**

Of 307 HBeAg negative and HBeAg positive patients who received treatment with VIREAD for up to 240 weeks in studies 0102 and 0103, genotypic analysis was performed on HBV isolates for all patients with HBV DNA > 400 copies/mL (n=4). No amino acid substitutions occurred in these subjects’ isolates which were associated with tenofovir resistance.

In studies 0102 and 0103, 160 patients treated with HEPSERA for 48 weeks, rolled over to treatment with VIREAD for up to 192 weeks; one patient with HBV DNA remaining > 400 copies/mL was evaluated for resistance. No amino acid substitutions were observed at sufficient frequency to establish an association with tenofovir resistance.

Among the 53 treatment-experienced patients in study 0106 treated with VIREAD, 17 had HBV DNA > 400 copies/mL following up to 48 weeks of treatment with VIREAD. Among these patients, no amino acid substitutions were observed in association with tenofovir resistance.

In study 0108, 45 patients (including 9 patients with lamivudine and/or adefovir resistance substitutions at baseline) received VIREAD for up to 48 weeks; 6 with HBV DNA > 400 copies/mL were evaluated for resistance. No amino acid substitutions associated with tenofovir resistance were identified in these isolates.

In studies 0102, 0103 and 0106, 12 patients randomised to VIREAD had HBV containing lamivudine-resistance associated substitutions at baseline. Following up to 48 weeks (0106; n=7) or 240 weeks (0102 and 0103; n =4) of treatment with VIREAD, two patients in study 0106 had HBV DNA > 400 copies/mL; no amino acid substitutions were observed in association with tenofovir resistance.

In studies 0102, 0103 and 0106, 13 patients treated with VIREAD had adefovir-resistance associated substitutions at baseline. Following up to 48 weeks (0106; n=8) or 240 weeks (0102 and 0103; n=5) of treatment with VIREAD, one patient in study 0103 and two patients in study 0106 had HBV DNA > 400 copies/mL; no amino acid substitutions were observed in association with tenofovir resistance.

In a paediatric study (GS-US-174-0115), HBV isolates from 5 patients who had plasma HBV DNA > 400 copies/mL were evaluated for tenofovir resistance-associated substitutions. No amino acid substitutions associated with resistance to VIREAD were identified in these isolates by Week 72.

**Cross Resistance**

Cross-resistance has been observed among HBV reverse transcriptase inhibitors. In cell based assays, HBV strains expressing the rtV173L, rtL180M and rtM204I/V mutations associated with resistance to lamivudine, telbivudine and reduced susceptibility to entecavir showed a susceptibility to tenofovir ranging from 0.7 to 3.4-fold that of wild type virus. HBV strains expressing the rtL180M, rtT184G, rtS202G/I, rtM204V and rtM250V mutations associated with resistance to entecavir showed a susceptibility to tenofovir ranging from 0.6 to 6.9-fold that of wild type virus. HBV strains expressing the adefovir-associated resistance mutations rtA181V and rtN236T showed a susceptibility to tenofovir ranging from 2.9 to 10-fold that of wild type virus. Viruses containing the rtA181T mutation remained susceptible to tenofovir with EC50 values 1.5-fold that of wild type virus.

**INDICATIONS**

VIREAD in combination with other antiretroviral agents is indicated for the treatment of HIV-infected adult and paediatric patients 12 years of age and older.

VIREAD is indicated for the treatment of chronic hepatitis B in adults (see CLINICAL TRIALS).

VIREAD is indicated for the treatment of chronic hepatitis B in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels or evidence of active inflammation.

**CONTRAINDICATIONS**

Known hypersensitivity to tenofovir, tenofovir disoproxil fumarate, or to any of the excipients in the film-coated tablets.

VIREAD must not be administered to children less than 12 years of age until further data become available.

VIREAD should not be administered concurrently with TRUVADA (emtricitabine / tenofovir disoproxil fumarate combination tablet), ATRIPLA (tenofovir disoproxil fumarate / emtricitabine / efavirenz combination tablet), EVIPLERA (tenofovir disoproxil fumarate/ emtricitabine/ rilpivirine combination tablet STRIBILD (tenofovir disoproxil fumarate/ emtricitabine / elvitegravir / cobicistat) or HEPSERA (adefovir dipivoxil).

**PRECAUTIONS**

###### **General**

Patients receiving VIREAD or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

Patients should be advised that antiretroviral therapies, including VIREAD, have not been proven to prevent the risk of transmission of HIV or HBV to others through sexual contact or blood contamination. Appropriate precautions must continue to be used. Patients should also be informed that VIREAD is not a cure for HIV infection.

HIV antibody testing should be offered to all HBV-infected patients before initiating VIREAD therapy (see PRECAUTIONS: HIV and HBV co-infection).

In the treatment of chronic hepatitis B, limited data are currently available in immuno-suppressed patients or those receiving immuno-suppressive regimens, orthotrophic liver transplant patients and patients coinfected with the hepatitis C or D virus. As clinical studies have not included sufficient numbers of subjects to determine whether these patients respond differently to VIREAD chronic hepatitis B therapy, such patients should be closely monitored.

***Use in children:***

The safety and efficacy of VIREAD in paediatric patients aged 12 to <18 years is supported by data from two randomised studies in which VIREAD was administered to HIV-infected treatment experienced patients and patients with chronic hepatitis B (see CLINICAL TRIALS and ADVERSE EFFECTS). The safety and efficacy of VIREAD has not been established in children less than 12 years of age.

The clinical relevance of the long term effects of tenofovir disoproxil fumarate treatment on BMD are unknown, and at present the data on the reversibility of renal toxicity effects is limited. Therefore, a multidisciplinary approach is recommended to consider the benefit/risk balance of treatment.

As hepatitis B is a chronic disease of the liver, ongoing clinical monitoring is recommended.

***Use in the elderly:***

VIREAD has not been studied in patients over the age of 65. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy (see DOSAGE AND ADMINISTRATION).

***Impaired renal function:***

Dosing interval adjustment is required in all patients with creatinine clearance <50 ml/min (See DOSAGE AND ADMINISTRATION). The proposed dose interval modifications are based on limited data and may not be optimal. The safety and efficacy of these dosing interval adjustment guidelines have not been clinically evaluated, and so the potential benefit of VIREAD therapy should be assessed against the potential risk of renal toxicity. Therefore, clinical response to treatment and renal function should be closely monitored in these patients.

Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphataemia), has been reported in association with the use of VIREAD (see ADVERSE EFFECTS: Post Marketing Experience).

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent.

It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy and, as clinically appropriate, during VIREAD therapy. Patients at risk for, or with a history of, renal dysfunction, including patients who have previously experienced renal events while receiving HEPSERA, should be routinely monitored for changes in serum creatinine and phosphorus.

***Lactic Acidosis/Severe Hepatomegaly with Steatosis:***

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination, including tenofovir disoproxil fumarate, in the treatment of HIV infection. A majority of these cases have been reported in women. The preclinical and clinical data suggest that the risk of occurrence of lactic acidosis, a class effect of nucleoside analogues is low for tenofovir disoproxil fumarate. However, as tenofovir is structurally related to nucleoside analogues, this risk cannot be excluded. Caution should be exercised when administering VIREAD to any patient, and particularly to those with known risk factors for liver disease. Treatment with VIREAD should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity.

***Drug interactions:***

Based on the results of *in vitro* experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low.

Tenofovir is excreted renally. Coadministration of VIREAD with medicinal products that decrease or compete for renal clearance may increase serum concentrations of tenofovir.

VIREAD has been evaluated in healthy volunteers in combination with abacavir, , didanosine, efavirenz, emtricitabine (EMTRIVA), entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, oral contraceptives, ribavirin, and tacrolimus (refer to Tables 2 and 3).

When administered with VIREAD, Cmax and AUC of didanosine administered as either the buffered or enteric-coated formulation at a dose of 400 mg daily increased significantly (see Table 4). The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse events, including pancreatitis, lactic acidosis and neuropathy. Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily. In patients weighing ≥60kg, the didanosine dose should be reduced to 250 mg when it is co-administered with VIREAD. Data are not available to recommend a dose adjustment of didanosine for adult or paediatric patients weighing <60 kg. When co-administered, VIREAD and didanosine EC may be taken under fasted conditions or with a light meal (<400 kcal, 20% fat). Co-administration of didanosine buffered tablet formulation with VIREAD should be under fasted conditions. Co-administration of VIREAD and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse events. Didanosine should be discontinued in patients who develop didanosine-associated adverse events.

Tenofovir disoproxil fumarate affects the pharmacokinetics of atazanavir. VIREAD should only be administered with boosted atazanavir (ATZ 300mg/RTV 100mg). The safety and efficacy of this regimen has been substantiated over 48 weeks in a clinical study.

Since tenofovir is primarily eliminated by the kidneys, co-administration of VIREAD with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs.

***HIV and HBV co-infection:***

Due to the risk of development of HIV resistance, VIREAD should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients.

***Exacerbation of Hepatitis After Discontinuation of Treatment:*** Discontinuation of anti-HBV therapy, including VIREAD may be associated with severe acute exacerbations of hepatitis. Patients infected with HBV who discontinue VIREAD should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of anti-hepatitis B therapy may be warranted. In patients with advanced liver disease or cirrhosis, discontinuation of anti-hepatitis B therapy is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.

***Early Virologic Failure:***

Clinical studies in HIV-infected patients have demonstrated that certain regimens that only contain three nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing two NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance mutations have been reported in clinical studies of combinations of tenofovir, lamivudine and abacavir or tenofovir, lamivudine and didanosine. Triple nucleoside regimens should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.

***Immune Reconstitution Syndrome:***

In HIV-infected patients with severe immune deficiency at the time of initiation of antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of antiretroviral therapy. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and *Pneumocystis joroveci* pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

***Lipodystrophy***

In HIV infected patients redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving combination antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established

***Carcinogenicity and Mutagenicity:***

In a long-term carcinogenicity study conducted in mice with tenofovir disoproxil fumarate there was a low incidence of duodenal tumours with the highest dose of 600 mg /kg/day. These were associated with a high incidence of duodenal mucosal hyperplasia, which was also observed with a dose of 300 mg/kg/day. These findings may be related to high local drug concentrations in the gastro-intestinal tract, likely to result in much higher exposure margins than that based on the AUC. At therapeutic doses the risk of these duodenal effects occurring in humans is likely to be low. The systemic drug exposure (AUC) with the 600 mg/kg/day dose was approximately 15 times the human exposure at the therapeutic dose of 300 mg/day. No tumourigenic response was observed in rats treated with doses of up to 300 mg/kg/day (5 times the human systemic exposure at the therapeutic dose based on AUC).

Tenofovir disoproxil fumarate was mutagenic in an *in vitro* mouse L5178Y lymphoma cell assay (*tk* locus) and in an *ex vivo* assay for unscheduled DNA synthesis in rat hepatocytes, but it was negative in *in vitro* bacterial assays for gene mutation and an *in vivo* mouse micronucleus test for chromosomal damage. Tenofovir base was not active in *in vitro* bacterial assays for gene mutation, and an equivocal response was seen in the *in vitro* mouse L5178Y lymphoma assay at a high concentration.

***Impairment of fertility:***

Male and female rat fertility and mating performance or early embryonic development were unaffected by an oral tenofovir disoproxil fumarate dose (600 mg/kg/day) that achieved systemic drug exposures that were in excess of the value in humans receiving the therapeutic dose (5-fold based on plasma AUC). There was, however, an alteration of the oestrous cycle in female rats.

***Use in pregnancy:***

Pregnancy Category **B3**. No clinical data are available for pregnant women being treated with VIREAD. Reproductive toxicity studies performed in rats and rabbits did not reveal any evidence of harm to the foetus due to tenofovir at respective exposures (AUC) of 4-13 and 66-fold the human exposure. Subcutaneous treatment of pregnant rhesus monkeys with a dose of 30 mg/kg/day of the tenofovir base during the last half of pregnancy resulted in reduced foetal serum phosphorus concentrations. Because animal reproduction studies are not always predictive of human response, VIREAD should be used during pregnancy only if clearly needed***.***

***Use in lactation:***

In animal studies tenofovir was excreted in milk after oral administration of tenofovir disoproxil fumarate (rats) and after subcutaneous administration of tenofovir base (non-human primates). In humans, samples of breast milk obtained from five HIV-1 infected mothers show that tenofovir is secreted in human milk at low concentrations (estimated neonatal concentrations 128 to 266 times lower than the tenofovir IC50 (50% maximal inhibitory concentration). Tenofovir associated risks, including the risk of developing viral resistance to tenofovir, in infants breastfed by mothers being treated with tenofovir disoproxil fumarate are unknown. It is recommended that HIV and HBV infected women do not breast-feed their infants in order to avoid transmission of HIV and HBV to the infant.

***Bone Effects:***

Bone toxicities including a reduction in bone mineral density (BMD) have been observed in studies in three animal species (see Animal Toxicology, below). Clinically relevant bone abnormalities have not been seen in long term clinical studies in adults (>3 years).

Bone abnormalities may be associated with proximal renal tubulopathy (see ADVERSE EFFECTS: Post-Marketing Surveillance).If bone abnormalities are suspected during therapy then appropriate consultation should be obtained.

There is limited clinical experience with VIREAD in paediatric patients. In a clinical study of HIV-1 infected paediatric patients 12 years of age and older (Study 0321), bone effects were similar to adult patients. Under normal circumstances BMD increases rapidly in this age group. In this study, the mean rate of bone gain was less in the VIREAD-treated group compared to the placebo group. Six VIREAD treated patients and one placebo treated patient had significant (>4%) lumbar spine BMD loss in 48 weeks. Markers of bone turnover in VIREAD-treated paediatric patients 12 years of age and older suggest increased bone turnover, consistent with the bone effects observed in adults. The effects of VIREAD-associated changes in BMD and biochemical markers on long-term bone health and fracture risk are unknown. In a clinical study (Study 115) conducted in paediatric subjects 12 years of age and older with chronic HBV infection, both the VIREAD and placebo treatment arms experienced an overall increase in mean spine BMD, as expected for an adolescent population. The percent increase from baseline in spine BMD in VIREAD-treated subjects was less than the increase observed in placebo-treated subjects. During the study, three subjects in the VIREAD group and two subjects in the placebo group had a decrease of more than 4% in lumbar spine BMD.

***Animal Toxicology:***

Tenofovir and tenofovir disoproxil fumarate administered in toxicology studies to rats, dogs and monkeys at exposures (based on AUCs) between 6 and 12 fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity in unknown.

Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia and /or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2-20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.

***Effects on ability to drive and use machines:***

No studies on the effects on ability to drive or use machines have been performed. However, patients should be informed that dizziness has been reported during treatment with tenofovir disoproxil fumarate.

**ADVERSE EFFECTS**

From Clinical Studies

***Clinical Trials in Adult Patients with HIV Infection:***

More than 12,000 patients have been treated with VIREAD alone or in combination with other antiretroviral medicinal products for periods of 28 days to 215 weeks in Phase I-III clinical trials and expanded access studies. A total of 1,544 patients have received VIREAD 300 mg once daily in Phase I-III clinical trials; over 11,000 patients have received VIREAD in expanded access studies.

***Treatment-Experienced Adult Patients***

**Treatment-Emergent Adverse Events:** The most common adverse events that occurred in patients receiving VIREAD with other antiretroviral agents in clinical trials were mild to moderate gastrointestinal events, such as nausea, diarrhoea, vomiting and flatulence. Less than 1% of patients discontinued participation in the clinical studies due to gastrointestinal adverse events (Study 907).

A summary of treatment-emergent adverse events that occurred during the first 48 weeks of Study 907 is provided in Table 14 (below).

# **Table 14. Selected Treatment-Emergent Adverse Events (Grades 2–4) Reported in ≥3% in Any Treatment Group in Study 907 (0–48 weeks)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **VIREAD (N=368) (Week 0–24)** | **Placebo (N=182) (Week 0–24)** | **VIREAD (N=368) (Week 0–48)** | **Placebo Crossover to VIREAD (N=170) (Week 24–48)** |
| Body as a Whole |  |  |  |  |
| Asthenia | 7% | 6% | 11% | 1% |
| Pain | 7% | 7% | 12% | 4% |
| Headache | 5% | 5% | 8% | 2% |
| Abdominal Pain | 4% | 3% | 7% | 6% |
| Back Pain | 3% | 3% | 4% | 2% |
| Chest Pain | 3% | 1% | 3% | 2% |
| Fever | 2% | 2% | 4% | 2% |
| Digestive System |  |  |  |  |
| Diarrhoea | 11% | 10% | 16% | 11% |
| Nausea | 8% | 5% | 11% | 7% |
| Vomiting | 4% | 1% | 7% | 5% |
| Anorexia | 3% | 2% | 4% | 1% |
| Dyspepsia | 3% | 2% | 4% | 2% |
| Flatulence | 3% | 1% | 4% | 1% |
| Respiratory |  |  |  |  |
| Pneumonia | 2% | 0% | 3% | 2% |
| Nervous System |  |  |  |  |
| Depression | 4% | 3% | 8% | 4% |
| Insomnia | 3% | 2% | 4% | 4% |
| Peripheral Neuropathy1 | 3% | 3% | 5% | 2% |
| Dizziness | 1% | 3% | 3% | 1% |
| Skin and Appendage |  |  |  |  |
| Rash Event2 | 5% | 4% | 7% | 1% |
| Sweating | 3% | 2% | 3% | 1% |
| Musculoskeletal |  |  |  |  |
| Myalgia | 3% | 3% | 4% | 1% |
| Metabolic |  |  |  |  |
| Weight Loss | 2% | 1% | 4% | 2% |

1. Peripheral neuropathy includes peripheral neuritis and neuropathy.

2. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.

**Laboratory Abnormalities:** Laboratory abnormalities observed in this study occurred with similar frequency in the VIREAD and placebo-treated groups. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 15 below.

Table 15. Grade 3 / 4 Laboratory Abnormalities Reported in ≥1% of VIREAD-Treated Patients in Study 907 (0–48 weeks)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **VIREAD (N=368) (Week 0–24)** | **Placebo (N=182) (Week 0–24)** | **VIREAD (N=368) (Week 0–48)** | **Placebo Crossover to VIREAD (N=170) (Week 24–48)** |
| **(%)** | **(%)** | **(%)** | **(%)** |
| Any ≥ Grade 3 Laboratory Abnormality | 25% | 38% | 35% | 34% |
| Triglycerides (>750 mg/dL) | 8% | 13% | 11% | 9% |
| Creatine Kinase  (M: >990U/L)  (F: >845 U/L) | 7% | 14% | 12% | 12% |
| Serum Amylase (>175 U/L) | 6% | 7% | 7% | 6% |
| Urine Glucose (≥3+) | 3% | 3% | 3% | 2% |
| AST (M: >180 U/L) (F: >170 U/L) | 3% | 3% | 4% | 5% |
| ALT (M: >215 U/L) (F: >170 U/L) | 2% | 2% | 4% | 5% |
| Serum Glucose (>250 U/L) | 2% | 4% | 3% | 3% |
| Neutrophils (<750 mg/dL) | 1% | 1% | 2% | 1% |

***Treatment-Naïve Adult Patients***

**Treatment-Emergent Adverse Events:** The adverse reactions seen in a double‑blind active controlled study in which 600 treatment-naïve patients received VIREAD (N=299) or d4T (N=301) in combination with lamivudine and efavirenz for 144 weeks (Study 903) were generally consistent, with the addition of dizziness, with those seen in treatment-experienced patients (Table 16).

Mild adverse events (Grade 1) were common with a similar incidence in both arms, and included dizziness, diarrhoea and nausea.

**Table 16. Selected Treatment-Emergent Adverse Events (Grades 2–4) Reported in ≥5% in Any Treatment Group in Study 903 (0–144 weeks)**

|  |  |  |
| --- | --- | --- |
|  | **VIREAD+3TC+EFV** | **d4T+3TC+EFV** |
| **N=299** | **N=301** |
| Body as a Whole |  |  |
| Headache | 14% | 17% |
| Pain | 13% | 12% |
| Back Pain | 9% | 8% |
| Fever | 8% | 7% |
| Abdominal Pain | 7% | 12% |
| Asthenia | 6% | 7% |
| Digestive System |  |  |
| Diarrhoea | 11% | 13% |
| Nausea | 8% | 9% |
| Vomiting | 5% | 9% |
| Dyspepsia | 4% | 5% |
| Metabolic Disorders |  |  |
| Lipodystrophy | 1% | 8% |
| Musculoskeletal |  |  |
| Arthralgia | 5% | 7% |
| Myalgia | 3% | 5% |
| Nervous System |  |  |
| Depression | 11% | 10% |
| Anxiety | 6% | 6% |
| Insomnia | 5% | 8% |
| Dizziness | 3% | 6% |
| Peripheral neuropathy1 | 1% | 5% |
| Respiratory |  |  |
| Pneumonia | 5% | 5% |
| Skin and Appendages |  |  |
| Rash Event2 | 18% | 12% |

1. Peripheral neuropathy includes peripheral neuritis and neuropathy
2. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash

**Laboratory Abnormalities:** With the exception of triglyceride elevations that were more common in the d4T group (14%) compared with VIREAD (3%), laboratory abnormalities observed in this study occurred with similar frequency in the VIREAD and d4T treatment arms. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 17.

**Table 17. Grade 3/4 Laboratory Abnormalities Reported in ≥ 1% of VIREAD-Treated Patients in Study 903 (0–144 weeks)**

|  |  |  |
| --- | --- | --- |
|  | **VIREAD+3TC+EFV** | **d4T+3TC+EFV** |
| **N=299** | **N=301** |
| Any ≥ Grade 3 Laboratory Abnormality | 36% | 42% |
| Creatine Kinase (M: > 990 U/L)  (F: > 845 U/L) | 12% | 12% |
| Serum Amylase (>175 U/L) | 9% | 8% |
| AST (M: >180 U/L) (F: >170 U/L) | 5% | 7% |
| ALT (M: >215 U/L) (F: >170 U/L) | 4% | 5% |
| Haematuria (>100 RBC/HPF) | 7% | 7% |
| Neutrophil (<750/mm3) | 3% | 1% |
| Triglyceride (>750 mg/dL) | 3% | 13% |

**Study 934 - Treatment Emergent Adverse Events:** Study 934 was an open-label active-controlled study in which 511 antiretroviral-naïve patients received either VIREAD + EMTRIVA administered in combination with efavirenz (n=257) or Combivir (lamivudine/zidovudine) administered in combination with efavirenz (n=254). Adverse events observed in this study were generally consistent with those seen in previous studies in treatment-experienced or treatment-naïve patients (Table 18). Adverse events leading to study drug discontinuation occurred in significantly smaller number of patients in the TRUVADA (tenofovir DF/emtricitabine) group compared to the Combivir group (5% vs 11%, p=0.010). The most frequently occurring adverse event leading to study drug discontinuation was anaemia (including decreased haemoglobin), no patient in the TRUVADA group and 6% of patients in the Combivir group.

**Table 18. Frequency of Adverse Reactions to EMTRIVA and/or VIREAD (Grade 2 – 4) Occurring in ≥3% of Patients Receiving EMTRIVA and VIREAD (or TRUVADA) in Study 934 (0-144 Weeks)1**

|  |  |  |
| --- | --- | --- |
| **Adverse Reaction** | **TRUVADA2 +EFV**  **N=257** | **Combivir + EFV**  **N=254** |
| Gastrointestinal Disorders  Diarrhoea  Nausea | 9%  9% | 5%  7% |
| Nervous System Disorders  Headache  Dizziness | 6%  8% | 5%  7% |
| Psychiatric Disorders  Insomnia  Abnormal Dreams | 5%  4% | 7%  3% |
| Skin and Subcutaneous Tissue Disorders  Rash | 5% | 4% |

1. Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to

study drug.

2. Patients received VIREAD + EMTRIVA up to week 96 and switched to TRUVADA from week 96 to 144.

**Laboratory Abnormalities:** Laboratory abnormalities observed in this study were generally consistent with those seen in previous studies (Table 19).

**Table 19 Grade 3/4 Laboratory Abnormalities Reported in** >**1% of Patients in Either Treatment Group, Study 934 (0–144 weeks)**

|  |  |  |
| --- | --- | --- |
|  | **TRUVADA1 + EFV**  **N=254** | **Combivir + EFV**  **N=251** |
| Any ≥ Grade 3 Laboratory  Abnormality | 30% | 26% |
| Creatine Kinase  (M: >990 U/L)  (F: >845 U/L) | 9% | 7% |
| Serum Amylase (>175 U/L) | 8% | 4% |
| AST  (M: >180 U/L)  (F: >170 U/L) | 3% | 3% |
| ALT  (M: >215 U/L)  (F: >170 U/L) | 2% | 3% |
| Hyperglycaemia (>250 mg/dL) | 2% | 1% |
| Haematuria (>75 RBC/HPF) | 3% | 2% |
| Neutrophil (<750/mm3) | 3% | 5% |
| Triglyceride (>750 mg/dL) | 5% | 3% |
| Haemoglobin (<7.0 g/dL) | 0% | 2% |

1. Patients received VIREAD + EMTRIVA up to week 96 and switched to TRUVADA from week 96 to 144.

***Clinical Trials in Paediatric Patients 12 Years of Age and Older with HIV Infection:***

Assessment of adverse reactions is based on one randomised study (study 321) in 87 HIV-infected paediatric patients (12 to 18 years of age) who received treatment with VIREAD (n=45) or placebo (n=42) in combination with other antiretroviral agents for 48 weeks. The adverse reactions observed in paediatric patients 12 years of age and older who received treatment with VIREAD were consistent with those observed in clinical studies in adults. Bone effects similar to those seen in adults were observed in this study (see PRECAUTIONS).

***Clinical Trials in Adult Patients with Hepatitis B:***

Assessment of adverse reactions is based on experience in two double-blind comparative controlled studies (0102 and 0103) in which 641 patients with chronic hepatitis B and compensated liver disease received treatment with VIREAD 300 mg daily (n=426) or HEPSERA 10 mg daily (n=215) for 48 weeks (see Table 20).

The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ class and frequency. Frequencies are defined as common (≥ 1/100, < 1/10).

*Gastrointestinal disorders:*

Common: nausea

|  |  |  |
| --- | --- | --- |
| **Table 20. Most Frequent (>5%) Treatment-Emergent Adverse Events of Any Severity**  **(Integrated RAT analysis set; 48-week Data from Studies 102 and 103)** | | |
|  | **Overall** | **Overall** |
| **AEs by Preferred Terma (n, %)b** | **TDF (N=426)** | **ADV (N=215)** |
| Any Adverse Event | 317 ( 74.4%) | 158 ( 73.5%) |
| Headache | 55 ( 12.9%) | 30 ( 14.0%) |
| Nasopharyngitis | 42 ( 9.9%) | 24 ( 11.2%) |
| Nausea | 40 ( 9.4%) | 6 ( 2.8%) |
| Fatigue | 36 ( 8.5%) | 16 ( 7.4%) |
| Abdominal Pain Upper | 30 ( 7.0%) | 11 ( 5.1%) |
| Back Pain | 30 ( 7.0%) | 10 ( 4.7%) |
| Diarrhoea | 28 ( 6.6%) | 11 ( 5.1%) |
| Dizziness | 24 ( 5.6%) | 7 ( 3.3%) |
| Procedural Pain | 16 ( 3.8%) | 12 ( 5.6%) |
| Pharyngolaryngeal Pain | 15 ( 3.5%) | 11 ( 5.1%) |
| Upper Respiratory Tract Infection | 13 ( 3.1%) | 11 ( 5.1%) |
| a Events coded using MedDRA dictionary version 9.1.  b Subjects are counted once only for each system organ class and preferred term, counting the most severe occurrence. | | |

**Laboratory Abnormalities:** A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 21.

**Table 21. Grade 3/4 Laboratory Abnormalities Reported in ≥1% of VIREAD-Treated Patients in Studies 0102 and 0103 (0-48 weeks)**

|  |  |  |
| --- | --- | --- |
|  | **VIREAD**  **(N=426)** | **HEPSERA**  **(N=215)** |
| Any ≥ Grade 3 Laboratory Abnormality | 19% | 13% |
| Creatine Kinase (M: >990 U/L; F: >845 U/L) | 2% | 3% |
| Serum Kinase (>175 U/L) | 4% | 1% |
| Glycosuria (≥ 3+) | 3% | < 1% |
| AST (M: >180 U/L; F: >170 U/L) | 4% | 4% |
| ALT (M: >215 U/L; F: >170 U/L) | 10% | 6% |

*Treatment beyond 48 weeks:* The adverse reactions observed with continued treatment for 240 weeks were consistent with the safety profile of VIREAD. Grade 3/4 laboratory abnormalities were similar in nature and frequency in patients continuing treatment for up to 240 weeks in these studies.

*Nucleoside-Experienced Patients:* No new adverse reactions to VIREAD were identified in those patients in studies 0102, 0103 and 0106 who had been previously treated with HEPSERA, lamivudine or other nucleoside analogs (n=352).

*Patients with Decompensated Liver Disease:* No new adverse reactions to VIREAD were identified from a double-blind active-controlled study (0108) in which patients with decompensated liver disease received treatment with VIREAD (n=45) for 48 weeks. Among the 45 subjects receiving VIREAD, the most frequently reported treatment-emergent adverse reactions of any severity were abdominal pain (22%), nausea (20%), insomnia (18%), pruritus (16%), vomiting (13%), dizziness (13%), and pyrexia (11%). Two of 45 (4%) subjects died through Week 48 of the study due to progression of liver disease. Three of 45 (7%) subjects discontinued treatment due to an adverse event. Four of 45 (9%) subjects experienced a confirmed increase in serum creatinine of 0.5 mg/dL (1 subject also had a confirmed serum phosphorus < 2mg/dL through Week 48). Three of these subjects (each of whom had a Child-Pugh score ≥ 10 and MELD score ≥ 14 at entry) developed renal failure. Because both VIREAD and decompensated liver disease may have an impact on renal function, the contribution of VIREAD to renal impairment in this population is difficult to ascertain.

One of 45 subjects experienced an on-treatment hepatic flare during the 48 Week study.

***Clinical Trials in Paediatric Patients 12 Years of Age and Older with HBV Infection:***

Assessment of adverse reactions is based on one randomised study (study 0115) in 106 paediatric patients (12 to < 18 years of age) infected with chronic hepatitis B receiving treatment with VIREAD (n=52) or placebo (n=54) for 72 weeks. The adverse reactions observed in paediatric patients who received treatment with VIREAD were consistent with those observed in clinical studies in adults (see ADVERSE REACTIONS).

Post Marketing Experience

In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of VIREAD. Because these events have been reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

IMMUNE SYSTEM DISORDERS

Allergic reaction (including angioedema)

METABOLISM AND NUTRITION DISORDERS

Hypokalaemia, hypophosphataemia, lactic acidosis

RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS

Dyspnoea

GASTROINTESTINAL DISORDERS

Increased amylase, abdominal pain, pancreatitis,

HEPATOBILIARY DISORDERS

Hepatic steatosis, increased liver enzymes (most commonly AST, ALT, gamma GT), hepatitis

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

Rash

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS

Rhabdomyolysis, muscular weakness, myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures)

RENAL AND URINARY DISORDERS

Increased creatinine, renal insufficiency, renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, nephrogenic diabetes insipidus, proteinuria, acute tubular necrosis, polyuria, interstitial nephritis (including acute cases).

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS

Asthenia

Reactions as a consequence of Proximal Renal Tubulopathy: The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), hypokalaemia, muscular weakness, myopathy, hypophosphataemia. These events are not considered to be causally associated with tenofovir DF therapy in the absence of proximal renal tubulopathy.

Immune Reconstitution Syndrome: In HIV-infected patients with severe immune deficiency at the time of initiation of antiretroviral therapy, an inflammatory reaction to infectious pathogens (active or inactive) may arise (see PRECAUTIONS).

In HBV infected patients, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of HBV therapy (see PRECAUTIONS).

***Adverse reactions attendant to class:*** Nephrotoxicity (elevation in serum creatinine and urine protein, and decrease in serum phosphorus) is the dose-limiting toxicity associated with other nucleotide analogues (cidofovir and high doses of adefovir dipivoxil evaluated for HIV disease (60 mg and 120 mg)).

**DOSAGE AND ADMINISTRATION**

***Adults:*** The recommended dose is 300 mg (one tablet) once daily taken orally. In order to optimise the absorption of tenofovir, it is recommended that VIREAD be taken with food.

***Paediatric Patients (≥ 12 Years of Age and ≥ 35 kg):*** The recommended dose for paediatric patients (12 years of age and older), who weigh ≥ 35 kg, is 300 mg (one tablet) once daily taken orally. In order to optimise the absorption of tenofovir, it is recommended that VIREAD be taken with food.

The safety and efficacy of VIREAD in patients under the age of 12 years have not been established. VIREAD must not be administered to children under 12, until further data become available.

***Elderly:***  No data are available on which to make a dose recommendation for patients over the age of 65 years. The safety and efficacy of VIREAD have not been established in patients over the age of 65 years. Caution should be exercised when administering VIREAD to elderly patients until further data become available describing the disposition of tenofovir disoproxil fumarate in these patients (see PRECAUTIONS). The greater frequency of decreased hepatic, renal or cardiac function in these patients, presence of any concomitant illnesses or the need for treatment with other medicinal products concomitantly with VIREAD should be taken into consideration.

***Renal impairment:*** Tenofovir is eliminated by renal excretion and the exposure to tenofovir increases in patients with renal dysfunction. Dosing interval adjustment is required in all patients with creatinine clearance <50 ml/min (calculated using the Cockcroft Gault equation), as detailed in Table 22 below. The proposed dose interval modifications are based on limited data and may not be optimal. The safety and efficacy of these dosing interval adjustment guidelines have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see PRECAUTIONS*).*

**Table 22. Dosage Adjustment for Adult Patients with Altered Creatinine Clearance**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Creatinine Clearance** **(mL/min)1** | | | **Haemodialysis Patients** | | |
|  | **≥50** | | **30–49** | **10–29** | |  |
| **Recommended 300 mg Dosing Interval** | Every 24 hours | | Every 48 hours | Every 72 to 96 hours | | Every 7 days or after a total of approximately 12 hours of dialysis2 |

1. Calculated with Cockcroft Gault equation.
2. Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. VIREAD should be administered following completion of dialysis.

The pharmacokinetics of tenofovir have not been evaluated in non-haemodialysis patients with creatinine clearance <10 mL/min; therefore, no dosing recommendation is available for these patients.

No data are available to make dose recommendations in paediatric patients 12 years of age and older with renal impairment.

***Hepatic impairment:*** There were no substantial alterations in tenofovir pharmacokinetics in patients with hepatic impairment compared with unimpaired patients. No change in VIREAD dosing is required in patients with hepatic impairment.

*Chronic hepatitis B:* Treatment with VIREAD may be discontinued if there is HBsAg loss or HBsAg seroconversion, otherwise the optimal duration of treatment is unknown.

**OVERDOSAGE**

Clinical experience of doses higher than the therapeutic dose of VIREAD 300 mg is available from two studies. In one study, intravenous tenofovir, equivalent to 16.7 mg/kg/day of tenofovir disoproxil fumarate, was administered daily for 7 days. In the second study, 600 mg of tenofovir disoproxil fumarate was administered to patients orally for 28 days.

No unexpected or severe adverse reactions were reported in either study. The effects of higher doses are not known.

If overdose occurs the patient must be monitored for evidence of toxicity (see ADVERSE EFFECTS and PRECAUTIONS), and standard supportive treatment applied as necessary.

Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour haemodialysis session removed approximately 10% of the administered tenofovir dose.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia) and 0800 764 766 (New Zealand).

**PRESENTATION AND STORAGE CONDITIONS**

Light blue, almond-shaped film-coated tablets, debossed on one side with the markings “GILEAD” and “4331” and on the other side with the marking “300”.

VIREAD is supplied in high density polyethylene (HDPE) bottles containing 30 film-coated tablets with a desiccant (silica gel canister or sachet) and polyester fibre packing material. Each bottle is capped with a polypropylene child-resistant closure with an induction-sealed, aluminium-faced liner.

Store below 25 °C

**NAME AND ADDRESS OF THE SPONSOR**

Gilead Sciences Pty Ltd

Level 6, 417 St Kilda Road

Melbourne, Victoria 3004

### POISONS SCHEDULE OF THE DRUG: S4

**Date of first inclusion on the ARTG:** 8 August 2002

**Date of most recent amendment:**  17 September 2013

VIREAD, EMTRIVA, TRUVADA, EVIPLERA STRIBILD and HEPSERA are registered trademarks of Gilead Sciences, Inc. ATRIPLA is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Other brands listed are trademarks of their respective owners and are not trademarks of Gilead Sciences, Inc, or Bristol-Myers Squibb & Gilead Sciences, LLC.